IDEAYA Reports Positive Interim Phase 2 Data For Darovasertib, Crizotinib Combination

April 24, 2023 — 09:22 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) reported further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma patients. The trial confirmed overall response rate of 45%, disease control rate of 90% and median PFS of approximately 7 months in 20 evaluable First-Line metastatic uveal melanoma patients.

IDEAYA is targeting to initiate a potential registration-enabling Phase 2/3 clinical trial in second quarter 2023 in first-line HLA-A2 negative MUM patients. The company said the Phase 2/3 clinical trial design incorporates guidance and feedback from the FDA following a recent Type C meeting.

IDEAYA stated that it had cash, cash equivalents and marketable securities of approximately $373 million as of December 31, 2022, which it currently projects will be sufficient to fund its planned operations into 2026.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

IDEAYA Reports Positive Interim Phase 2 Data For Darovasertib, Crizotinib Combination

Tags

Latest Articles